Clinical Trial Update: Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the correlation between soluble ST2 and response to Golimumab (MK-8259) in ulcerative colitis participants; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)
• MK-8259 (not specified)
• ST2 assay (Soluble suppression of tumorigenicity 2) (not applicable)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colitis, Ulcerative | Phase 4 | Status: COMPLETED | Results posted: 2018-08-20